plenary: address global eye care needs...a patient is young—think elemen-tary school age—and...

In 2000, 22.9% of patients globally had myopia, Erin C. Jenewein, OD, MS,

FAAO, and Nicholas Gidosh, OD, FAAO, told the audience of their Wednesday morning session, “Myopia Control as a New Standard of Care? Current Research and Clinical Applications.” Flashing for-ward to 2050, the presenters said recent fi ndings indicate that the incidence of myopia is expected to rise more than two-fold to around 50%. That’s half of the world popu-lation. Taking on this burden requires you fi rst know the basics.

Be on the LookoutFor the most part, Drs. Jenewein and Gidosh said myopia starts when

a patient is young—think elemen-tary school age—and continues into adulthood. They noted that patients who conduct sustained near work, spend limited time outdoors and

have myopic parents are at a high risk for developing the condition. Evaluat-ing patients for these risk factors, as well as refrac-tive error and progression rate, help determine who requires immediate atten-tion to ward off the risk of associated ocular health problems, such as retinal detachment, cataract, open-angle glaucoma, macular complications, blindness and visual impairment.

Take the Right RouteAfter identifying patients

at risk for myopia, Drs. Jenewein and Gidosh advised looking into several management options based on patient preference. While not as

Plenary: Address Global Eye Care Needs

With prevalence on the rise, we must be prepared to catch it, manage it and educate patients.

See MYOPIA, Page 5

Control Myopia Before it Controls You

REVIEW OF OPTOMETRY • AAO TIMES • OCTOBER 24, 2019

T H U R S D A Y , O C T O B E R , 2 4 , 2 0 1 9

This year’s photo contest winners, p.10 Exhibitor listing and hall map, p.8

Dr. Gidosh highlights what a soft multifocal contact lens should look like for myopes.

WHAT’S INSIDE• Plenary presents WHO’s Vision Report ... 3

• The OGS and the Academy team up to take on glaucoma ................................... 4

• Retina, vision research spotlights .......... 5

• Upcoming vision theater options ............ 5

• Section and SIG business meetings ....... 6

• Today’s CET course offerings ................. 6

• How to prescribe medications safely ..... 7

• Myopia research spotlight ...................... 7

• Exhibitor list and map ............................. 8

• 2019 photo contest winners ................. 10

• CEE course offerings this week ............ 12

• OWNS dinner lecture sneak-peek ........ 13

• Conjunctivitis, diabetes research spotlights .............................................. 13

• Ezell Fellows link data to patients ........ 14

We must start to understand that the world needs optometry,”

Academy President Barbara Caf-fery, OD, PhD, FAAO, stated at the beginning of yesterday’s Plenary Session, “WHO World Health Re-port: Opportunities for Optometry to Make an Impact.” The session outlined the problems in eye care as seen by the World Health Organi-zation’s (WHO) World Report on Vision and how optometry could embrace the report’s goal of making eye care an integral component of universal health coverage. Before the presentations commenced, Dr. Caffery charged the crowd, “The Academy exists to inspire you to use

your excellence to contribute to the resolution of these problems.”

Challenges and OpportunitiesAlarcos Cieza, PhD, who led the WHO report initiative, fi rst shared her experience with the overwhelm-ing amount of data her team compiled regarding the huge need for eye care around the world. Glob-ally, at least 2.2 billion people have vision impairment—one billion of which could have been prevented or has yet to be addressed, the report states.

Dr. Cieza also mentioned that, be-cause of the growing aging popula-

tion and modern lifestyles, we could expect an increase in the number of people with glaucoma, cataracts and age-related macular degeneration in the years to come. She added that

eye conditions that do not typically cause vision impair-ment, such as dry eye and conjunctivitis, should not be overlooked. These conditions are frequently the most com-mon reasons patients present to eye healthcare practitioners around the world.

Even in countries where eye care exists, it’s not necessar-ily accessible or affordable to everyone, Dr. Cieza said. In many countries, eye care

is not prioritized in the strategic planning of many health sectors. “We need to advocate to make sure

The new WHO report on vision impairment demands a sense of urgency and action from the profession.

See PLENARY, Page 3

Dr. Cieza from the WHO presents fi ndings that portray the current global need for eye care.

T Future Academy meeting cities and dates, p.6Fu

TIMES

2019__THURS.indd 12019__THURS.indd 1 10/23/19 10:22 PM10/23/19 10:22 PM

T H E R E ’ S R E L I E F A N D T H E N T H E R E ’ STM

Stop by Allergan booth 909

© 2019 Allergan. All rights reserved. All trademarks are the property of their respective owners. REF127449 08/19

refreshbrand.com/doc

THE ONLY FAMILY OF PRODUCTS IN THE U.S. WITH CMC, HA†, AND HYDROCELL™ TECHNOLOGY.

Welcome to REFRESH® RELIEVA™—the innovative family of products specially formulated to relieve discomfort due to eye dryness and prevent further irritation. We do it with HydroCell™ technology—our proprietary NaCl-free, glycerin-based solution that enables hydration and maintains the volume of cells on the ocular surface.

†HA is an inactive ingredient

AAO2019_Allergan.indd 1 10/18/19 11:33 AM

that eye care is thought of as an integral part of the health system that not only can be prioritized but also integrated and considered in the planning,” Dr. Cieza emphasized.

She also discussed how eye care can contribute to the WHO’s third Sustainable Development Goal: ensure healthy lives and promote well-being for all. According to Dr. Cieza, interventions in eye care are effective if health promotion, pre-vention, treatment and rehabilitation efforts address the entire range of needs associated with eye conditions and vision impairment throughout the course of their lives—from birth to death.

She concluded that we should con-tinue to monitor trends and evaluate progress 30 years from now.

Reflect and ReactKovin Naidoo, OD, PhD, FAAO, senior vice president of inclusive business, philanthropy and social impact at Essilor, and part of the editorial board for the WHO report, discussed how to make an impact with the information presented. Ac-cording to him, the WHO numbers encompass vision impairment and blindness, but also highlight how heath systems can reach the most vulnerable in society or, according to Dr. Naidoo, “the people who cannot function, cannot work and learn because their vision is so bad.”

Besides fostering a sense of frater-nity within all eye care professions, Dr. Naidoo highlighted that the ev-er-increasing scope of optometry has much to offer on the global scale.

“If we can export our expertise in a valid and relevant way, optometry institutions here can make a differ-ence by taking these lessons of how you can come up with systems to train people,” he said.

Dr. Naidoo touched on the easi-est opportunity the World Report on Vision presented: uncorrected refractive error is the second leading cause of blindness in the world, and uncorrected refractive error is the leading cause of visual impairment. “If we address these, we will move the needle,” he noted.

Dr. Naidoo also mentioned that optometrists are intimately familiar with myopia and diabetic retinopa-thy—two public health issues that will affect the aging population. “Yes, 50% of the world’s popula-tion will be short-sighted,” Dr. Naidoo conceded. “That is in your hands and mine.”

He concluded by encouraging op-tometrists in the United States to ac-tively participate on the global scale and support the international efforts working against vision impairment and other eye care burdens.

Eye Care for AllSandra Block, OD, MPH, FAAO, regional representative of North America in the World Council of Optometry, also contributed to the World Report on Vision and discussed how a country such as the United States with a developed healthcare system could address the increasing demands for eye care globally.

Integrating with the WHO’s goals of universal health coverage could

lead to better prevention, earlier detection, and improved access to diagnostic and therapeutic eye care, she said. “There’s a cost savings associated with doing a bet-ter job detecting these problems early, preventing

that disease from either taking over the patient or leading to signifi cant visual impairment and blindness,” Dr. Block said. “We need to look at how we can get a better return on investment.”

Dr. Block also touched on the great percentage of elderly individual, especially those at least 80 years old, who will face chronic vision impairment. Vi-sion impairment in the elderly often brings along cognitive and physi-cal functioning issues and multiple chronic comorbidities, she added.

“We need to be able to ensure that we allow this population to age gracefully,” she said. “We want

them to be able to be independent and engage them as part of the community rather than isolate or marginalize them.”

Dr. Block left the crowd with a lingering thought: “Do we just listen, or are we going to take some action?” •

3AAO TIMES


Plenary Evaluates WHO Vision ReportContinued from Page 1

Dr. Naidoo discusses how the WHO report magnifi es the role of optometry around the world.

Dr. Block outlined a framework for ensuring the US health system provides access for everyone.

TODAY’S HIGHLIGHTS

Nevin El-Nimri, OD, MS, FAAO, will be recognized during the Student and Resident Award Lunch today at noon in the Valencia Ballroom, W415 CD. Her presentation at Academy 2018 San Antonio was selected as the best student scientifi c presentation overall.

Hot Topics Paper Sessions, Today, 8–9amLectures won’t begin until 9am this morning, so join us at a Hot Topic Paper Session for some CE and information on the latest developments in the fi eld:• Hot Topics in Pediatrics and Binocular Vision, W224 EFG• Hot Topics in Glaucoma: Structure and Function, Tangerine WF1• Hot Topics in Anterior Segment, Tangerine WF2• Hot Topics in Artifi cial Intelligence, Tangerine WF 3/4

Special Evening Poster Event:, Tonight, 4:30–6:30pm in WD1 Stop by for CE and a complimentary cocktail (with ticket) during this special evening poster session. This will be a fun way to catch up on some of the latest research that will shape our profession in the years to come! Posters will be available to view starting at 9am. Poster topics will include:

• Cornea/ Anterior Segment/ External/ Dry Eye• Systemic & Other Disease• Glaucoma• Neuro-Ophthalmic & Orbit• Academy Information Posters

• Binocular Vision• Pediatric Optometry• Low Vision• Visual Function/Perception

Paper Sessions for Thursday, October 24:

Category Room Time

P-07: Myopia Super Session W224 ABC 9am–12pm

P-08: Papers: Anterior Segment W224 EFG 9am–10:45pm

P-09: Papers: Contact Lens Visual Performance W224 EFG 11am–12pm

P-10: Contact Lens Super Session W224 ABC 1:30–4:30pm

P-11: Papers: Posterior Segment W224 EFG 1:30–3pm

P-12: Papers: Clinical Electrophysiology W224 EFG 3:15–4:30pm



AAO TIMES4

Optometric Glaucoma Society (OGS) President Michael Chaglasian, OD, FAAO—

along with his co-moderator, OGS Secretary Danica Marrelli, OD, FAAO—invited attendees of this year’s conference to hear some of the recent research that has sparked the imaginations of the group.

New TargetsLouis R. Pasquale, MD, is ready for nitric oxide agonists and rho kinase inhibitors, he said, speaking fi rst at the morning meeting. He’s not alone in that view. In fact, with the recent FDA approval of topical agents that leverage nitric oxide signaling to improve aqueous humor dynam-ics, many optometrists who treat glaucoma are asking questions. Dr. Pasquale is confi dent in these agents.

“Nitric oxide is important in the natural physiology of intraocular pressure,” he said. “It is reasonable to use nitric oxide donators fairly early on in the treatment of primary open-angle glaucoma (POAG) pa-tients and even angle closure glau-coma who’ve been managed.” Dr. Pasquale, a researcher with the Icahn School of Medicine at Mount Sinai, explained that nitric oxide intracellu-lar cyclic guanylate monophosphate levels could be neuroprotective in glaucoma. He also discussed dietary options—such as green leafy veg-etables (even iceberg lettuce) and beets—to increase nitric oxide intake.

Speedy Delivery While Dr. Pasquale has his eye on the drugs themselves, Uday B. Kompella, PhD, who presented next, is interested in getting those vital glaucoma drugs into the eye and experimenting with delivery methods that work.

“At the end of the day, you have all these delivery systems, but what matters to the patient is effective-ness,” he said. It makes sense. Most ocular medications—be they drops, implants or inserts—are not ideal, so if patients are going to grin and bear them, they better at least work.

Dr. Kompella discussed the pros and cons of intracameral inserts, latanoprost-eluting contact lenses and punctal plugs as well as a whole host of nontraditional delivery methods such as ring-type systems, microspheres, nanospheres, gels and supraciliary and intravitreal inserts. Clearly, the developments in this area are wide-ranging, and manufac-turers and doctors alike are eager to see a device that can effectively and comfortably replace the daily drops for glaucoma patients for good.

Finding ClosureShan Lin, MD, of the Glaucoma Center of San Francisco, joined the presenters to discuss a different angle on glaucoma: angle closure. Some may consider it rare—whether it is or not isn’t fully clear—but it is certainly “a much more aggressive disease” than POAG and accounts for approximately half of all glauco-ma-related blindness, Dr. Lin said.

It’s also strongly hereditary. When a 52-year-old woman presented to Dr. Lin with an iris tumor, he dis-covered that she had angle closure. He asked her to send in her younger sister. And then her brother. And her mother. They all had undiagnosed angle-closure glaucoma. While Asian patients and those older than age 50 are more likely to have angle closure, the strongest risk factor is familial history. Gonioscopy remains the standard of care in evaluating these patients, but anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy can also be useful. In fact, Dr. Lin said “I probably trust my AS-OCT even more than gonioscopy at this point.”

But diagnosing angle-closure glaucoma patients is only part of the battle. Treating them is another skill set altogether. For instance, laser peripheral iridotomy (LPI) is a com-mon treatment for this condition, but newly published research advises against widespread LPIs, he said, referring to the Zhongshan Angle Closure Prevention Trial (ZAP trial).

Laser iridoplasty is another op-

tion, but Dr. Lin warns that, while it has immediate benefi ts to the angle’s diameter, the research really hasn’t shown any long-term benefi ts.

He also talked about endocyclo-plasty and the 2016 Effectiveness in Angle Closure Glaucoma of Lens Ex-traction (EAGLE) study’s support of clear lens extraction over iridotomy. LPI is still the fi rst line of defense, but newer research is suggesting clear lens extraction has a role for some patients, too. •

The joint presentation considered the latest studies on drugs, delivery devices and procedures.

Glaucoma Research in the Spotlight at OGS/AAO

NEW TECHNOLOGIES & TREATMENTS IN

Eye CareNEWNEW TE && T

EEEy

2019 ye CareCareCaCC re Ca EEEy9

Earn up to

19 CE Credits*

CHARLESTON, SOUTH CAROLINA

THREE WAYS TO REGISTER: Visit: www.ReviewsCE.com/Charleston2019

Call: 1-866-658-1772 E-mail: [email protected]

Date: November 1-3, 2019

Location: Charleston Marriott 170 Lockwood Boulevard Charleston, SC 29403 Phone: 843-723-3000

Program Chair: Paul M. Karpecki, OD, FAAO

Faculty: Marc Bloomenstein, OD, FAAO Douglas K. Devries, OD

Robert P. Wooldridge, OD, FAAO

Review Education Group partners with Salus University for those ODs who are licensed in states that require university credit. *This activity, COPE Activity Number 118364, is accredited by COPE for continuing education for optometrists. Approved by the Florida Board of Optometry.

*Approved

Administered by: Partially supported by unrestricted educational grants from:

Sun PharmaceuticalsBausch & LombCarl Zeiss Meditec

Alcon

Shan Lin, MD, offered his views on the ZAP and EAGLE studies to the Optometric Glaucoma Society

yesterday.


effective as other treatments, they noted that spectacles are a good option for patients who are unable or unwilling to wear contact lenses or use eye drops. For high myopes who are not candidates for corneal reshaping but are motivated to wear and take care of contact lenses, the duo suggested soft multifocals. They recommended ortho-K for those with less than -6.00D of myopia and -1.75D of corneal astigmatism.

They added that atropine can be combined with contact lenses and is a good solution for those willing to use daily drops and able to afford and ob-tain them from a compounding facility, as low-dose atropine is not yet FDA approved.

Arm YourselfDiagnosing and managing myopia means nothing without the proper staff training, provider knowledge and patient and parent education, Drs. Jen-ewein and Gidosh said. They noted that staff who know how to interact with patients, an eye care doctor who is able to transfer his expertise, a patient who is compliant and a parent who understands the process, expected out-comes and goals—to slow myopia progression and prevent irreversible vision loss—make for the best outcomes.

“Myopia is a growing epidemic, and myopia control is quickly becoming more of a standard practice, even in primary care optometry, so we encour-age you to offer it in your practice when a patient fi rst becomes myopic or even prior,” said Dr. Jenewein. •


5AAO TIMES

RESEARCH SPOTLIGHT

CINAPS - Convergence Insufficiency Neuro-Mechanism in Adult Population Study: Effect of Vision Therapy on Clinical, Objective Eye Movement and fMRI Measures Tara L. Alvarez, Mitchell M. Scheiman, Cristian Morales, et al.

Continued from Page 1

Myopia On the Rise

Vision Theater SessionsThese informative, commercial programs will be conducted by exhibitors in a specially constructed theater on the exhibit fl oor. Grab some lunch and have a seat! Pre-registration is required. Tickets were provided at registration.

Thursday, October 24

Company Time-Slot Location Speaker Title

Sun Ophthalmics

11–11:30amVision Theater 1

KarpeckiCequa (cyclosporine ophthalmic solu-tion) 0.09%, An Innovative Treatment Option for Dry Eye Patients

Glaukos12:20–12:50pm

Vision Theater 1

DierkerSafety and Effi cacy—Why iStent Injection is a Clear Choice

Allergan12:20–12:50pm

Vision Theater 2

Hom Insights in Dry Eye Management

Glaukos 1–1:30pmVision Theater 1

JedickaFinding the Right Fit with Zenlens and Zen RC Scleral Lenses

Friday, October 25

Company Time-Slot Location Speaker Title

Bausch + Lomb 11–11:30amVision Theater 1

Gerson Making Sense of Ocular Nutrition

Vertical Pharmaceuticals

11–11:30pmVision Theater 2

Korenfeld, Foster

Oxymetazoline HCL 0.1% solution: A Novel Investigational, Once a Day Pharmacologic Treatment for Acquired Blepharoptosis

Genentech 12:20–1:20pmVision Theater 1

Eichenbam, Ferrucci

Diagnosis and Treatment Considerations for Diabetic Retinopathy

Offi ce-based vergence and accommo-dative therapy can enact signifi cant

changes in clinical signs and symp-toms, disparity vergence responses and functional activity within the vergence neural circuit in young adults with symp-tomatic convergence insuffi ciency (CI). Investigators conducted vision therapy in 12, one-hour sessions. The study found improvements in near point of

convergence, positive fusional vergence at near, CI symptom survey and 5° disparity conver-gence peak velocity measure-ments post-vision therapy. “The ones that participated in offi ce based vergence and accommo-dative therapy improved to the point where they were healthy controls,” said Tara Alvarez, PhD.

Researchers from the Pediatric Eye Disease Investigator Group

(PEDIG) previously conducted a phase 1, dose de-escalation study of beva-cizumab for retinopathy of prematurity (ROP) and reported that very low doses (as low as 0.031mg) were effective in treating type 1 ROP.

At two years, 67 eyes had a cyclople-gic refraction. Excluding two aphakic eyes, mean spherical equivalent was -1.54 and nine eyes had myopia more than -5.00. Optic nerve atro-phy was identifi ed in six eyes, strabismus in 10, manifest nystagmus in three and amblyopia in two.

Ocular and Neurodevelopment Outcomes Two Years After Very Low-Dose Bevacizumab for Retinopathy of Prematurity Susan A. Cotter, David K. Wallace, Amra Hercinovic, et al.

The above summary was presented at the Academy press conference yesterday. Mr. Kraker will give a full presentation of the study today in this session:

Hot Topics in Pediatrics and Binocular Vision Thursday 8–9am, W224 EFG

The above summary was presented at the Academy press conference yesterday. Dr. Alvarez will give a full presentation of the study today in this session:

Hot Topics in Pediatrics and Binocular Vision Thursday 8–9:15am, W224 EFG

Therapy improves activity in the frontal, supplementary and parietal eye fi elds.


AAO TIMES6


Tonight, 8–10pm in Plaza International Ballroom, Hyatt Regency

Essilor Academic Challenge at Academy Stadium

Join us for the second annual Essilor Academic Challenge. This event is a team competition that will determine which school or college of optometry has what it takes to be crowned the champion. Will The Ohio State University take the title once again? Come fi nd out and cheer on your classmates or alma mater! Attendees will also be invited to join the after-party to celebrate the winning team.

Public Health and Environmental Vision Section Awards and Henry B. Peters Lecture Please join us today from 5:30–6:30pm to hear the Public Health and Environ-mental Vision Section Awards and the Henry B. Peters Lecture in W230 CD

Henry B. Peters Memorial Award in Public Health and Environmental Vision

Provided by the American Academy of Optometry Foundation

Robert N. Kleinstein, OD, PhD, FAAO

Lecture: Environmental Vision and Public Health (Environ-ment, Vision, Optometry, Opportunity)

CET COURSES – THURSDAY, OCTOBER 24Select courses have been submitted and approved for Continuing Education and Training (CET) points valid for optometry and optical professionals registered in the United Kingdom. Each course will be worth 1 CET point.


Time Course # Course Title Lecturer(s) Room

9–10am GL-04 Mistakes to Avoid in Glaucoma Joseph Sowka Tangerine WF2

2:30–3:30pm GO-10 Visual Fields in 2019: Still Relevant in Your Clinical Practice? Jack Phu W231

2:30–4:30pm GO-11 Myopia: 12 Evidence-based Things You Need to Know Mark Bullimore, Noel Brennan Tangerine WF2

4:30–5:30pm SD-10 When OCT Is Not Enough – A Multimodal Imaging Approach to Ocular Disease Diagnosis Michael Yapp Tangerine WF3/4

SECTION AND SIG BUSINESS MEETINGSSection/Special Interest Group Date/Time Location

Academic Medical Center Optometrists SIG Thursday, October 24, 6–8:30am TBD, invitation only

Neuro-ophthalmic Disorders in Optometry SIG Thursday, October 24, 7–8am Boardroom (Hyatt)

Retina SIG Thursday, October 24, 7–8:30am Bayhill 25 (Hyatt)

Nutrition, Disease Prevention & Wellness SIG Thursday, October 24, 5:30–7:30pm Bayhill 20 (Hyatt)

Public Health & Environmental Vision Section Thursday, October 24, 7–9pm Bayhill 24 (Hyatt)

Vision in Aging SIG Thursday, October 24, 6:30–8:30pm Bayhill 31-32 (Hyatt)

Vision Science SIG Thursday, October 24, 7:15–9:15pm Bayhill 29 (Hyatt)

Anterior Segment Section Friday, October 25, 7–8am Barrel Spring I (Hyatt)

Comprehensive Eye Care Section Friday, October 25, 7–8am Manatee Spring I (Hyatt)

Glaucoma Section Friday, October 25, 7–8am W330 (Convention Center)

Binocular Vision, Perception & Pediatric Optometry Section Friday, October 25, 12–1:30pm Barrel Spring I (Hyatt)

Section on Cornea, Contact Lenses & Refractive Technologies Saturday, October 26, 7–9am Coral Spring (Hyatt)

Academy 2020 Nashville October 7-10, 2020

Academy 2021 Boston November 3-6, 2021

Academy 2022 San Diego October 26-29, 2022

Academy 2023 New Orleans October 11-14, 2023

Academy 2024 Washington DC November 6-9, 2024

Academy 2025 Boston October 8-11, 2025

Academy 2026 San DiegoNovember 11-14, 2026

JOIN US AT THESE FUTURE ACADEMY MEETINGS!



7AAO TIMES

None of the drugs Greg Caldwell, OD, FAAO, and Tracy Offerdahl, BSc,

PharmD, plan to speak about at this morning presentation are uncom-mon and that’s exactly the point, according to Dr. Caldwell. Because even these commonly prescribed agents “can have very serious com-plications or adverse events,” he says. But fret not, for Dr. Caldwell and his pharmacist co-presenter Dr. Offerdahl have created a guide to avoiding, understanding and manag-ing these complications.

“When doing a lecture like this, my goal is not to scare the optometrist out of using these pharmaceuticals, but to know the potential adverse event and feel more comfort to prescribe these agents,” Dr. Caldwell explains.

Specifi cally, the duo will discuss the ocular complications—rare though they may be—of the different classes of antibiotics, alpha-1 blockers, anti-arrhythmics, anticonvulsants, autoimmune agents, drugs to treat osteoporosis and others.

They’ll share a series of real-life case examples to walk clinicians through the likely presentation of patients suffering from an adverse drug event.

Hopefully, attendees can learn from these experiences and then be able to recognize them, even in new patients, Dr. Caldwell suggests.

“By attending this lecture every optometrist will feel more comfort-able when prescribing these medica-tions or will feel more comfortable making sure the patient is not having an adverse event.”•

Know Your Pharma ComplicationsWith prescribing privileges comes a responsibility to understand how drugs interact.

TOMORROW 8-10AM TANGERINE WF2

Earn up to

17 CE Credits*

Early Bird Discount!

$545Must register before

12/1/2019

THE LONGEST RUNNING WINTER CE MEETING IN EYE CARE

February 14-17, 2020

The Westin Snowmass Conference Center

100 Elbert Lane, Snowmass Village, CO

Program Co-Chairs: Murray Fingeret, OD, FAAO

Leo P. Semes, OD, FACMO, FAAO

Featuring relevant topics in glaucoma, dry eye, external disease and retina.

www.SkiVision.com

p to

CEits*

EEaarly B

$$MMMMuMuusst re

12

A REVIEW MEETING OF CLINICAL EXCELLENCE

ANNUAL • EST. 1976

Review Education Group partners with Salus University for those ODs who are licensed in states that require university credit.

*Approval pending

Administered by:

You can learn to recognize the signs of toxic optic neuropathy due to amioda-rone use, and a host of other ills, at this morning’s talk on drug complications.

Photo

: Meg

an Hunter, O

D

RESEARCH SPOTLIGHT

A new analysis of data for visual impairment as a function of myopia has helped quan-

tify the potential of myopia control to lower the risk of visual impairment later in life. Applying a mortality table to a quantitative evidence-based approach comparing myopia control’s risks and benefi ts resulted in the frequency of visual impairment per 10,000 patients at different levels of myopia. “We can inte-grate the area under those curves, and the area under the curve is patient years of visual impairment,” Dr. Bullimore said. “And what we can then see is that if we can lower somebody by a diopter, we can save anywhere from a half to maybe one year of visual impairment in an individual patient.”

“So comparing the benefi ts and the risks, preventing one diopter of myopia through treatment should lower the years of visual impairment by between 5,000 and 10,000 years per 10,000 patients.”

Researchers also developed a math-ematical term that encompasses both age and level of myopia that in, unrefractive error, a diopter has more effect than one year of age, and fi ve years of myopia is equivalent to 12 years of aging in terms of risk exposure to the patient.

Myopia Control: An Evidence-Based Comparison of the Benefits and the RisksMark A. Bullimore, Eric R. Ritchey

The above summary was presented at the Academy press conference yesterday. Dr. Bullimore will give a full presentation of the study today in this session:

Myopia Super Session Thursday 9–9:15am, W224, ABC


REVIEW OF OPTOMETRY • SECO SHOW DAILY • MARCH 2, 2018REVIEW OF OPTOMETRY • AAO TIMES • OCTOBER 24, 2019

ABB Optical Group ............................................ 724AccuLens ........................................................... 625Acuity Pro Software ........................................... 929Adit .................................................................... 226Air Force Recruiting Service .............................. 222Alcon ................................................................. 916“Alcon Foundation “Hoop it Up” ....................... 231Allergan ............................................................. 909American Academy of Optometry .................... 1527Fellows Doing Reserch.................................... 1727Amer. Acad. of Optometry Foundation .............. 331Amer. Acad. of Ortho-K and Myopia Control .... 719Amer. Board Cert. Medical Optometry ............ 1709American Board of Opticianry & National Contact Lens Examiners ............... 1423American Board of Optometry ........................... 621Arbor Eyewear ................................................... 830Armed Forces Optometric Society ................... 1435Art Optical Contact Lens .................................. 1311Assn. of Schools and Colleges of Optometry ... 619Aventic Group .................................................... 735Bausch + Lomb ................................................. 801Benign Essential Blepharospasm Res. Fdn. ...... 302Bernell ............................................................. 1601Bio-Tissue ....................................................... 1701Blanchard Contact Lens .................................... 716BlephEx ............................................................. 930Brien Holden Vision Institute ............................ 117Bruder Healthcare Company ............................. 723Modern Optometry .......................................... 1310CareCredit ......................................................... 507CenterVue ........................................................ 1034Int’l Association of Contact Lens Educators ...... 730Choroideremia Research Foundation ................ 829Clerio Vision...................................................... 722Coburn Technologies ........................................ 702Color My World by Vivid Eyes ........................ 1231Compulink Healthcare Solutions ...................... 316Contamac .......................................................... 632CooperVision .................................................... 809Corporate Optometry ......................................... 225DemandForce .................................................. 1534Designer Drugs Pharmacy ................................ 831Designs for Vision ........................................... 1503Deux Mains Designs ......................................... 123DGH Technology ............................................... 617Diaton Tonometer .............................................. 127Digital Health Care Professionals ..................... 426Diopsys ........................................................... 1030Doctible ........................................................... 1707Elektron Eye Technology ................................... 324Elsevier .............................................................. 518Eschenbach Optik of America............................ 808Espansione Marketing Spa ................................ 535Essilor.............................................................. 1619Euclid Systems .................................................. 208Eye Care and Cure ............................................. 300EyeCare Partners ............................................. 1433EyecareLive........................................................ 307

Eyenovia ............................................................ 323EyePromise ....................................................... 728Eyeris ............................................................... 1608EyeSpace ........................................................... 111Eyevance Pharmaceuticals ................................ 629Florida Optometric Insurance Services ........... 1239Fortifeye Vitamins ............................................ 1604Frames Data ...................................................... 604Vispero .............................................................. 422Globechek........................................................ 1702Good-Lite Company ........................................ 1401Guardion Health Sciences ............................... 1711Gyroscope Therapeutics .................................... 227Haag-Streit USA/Reliance ................................. 101Healthy Eyes Advantage .................................. 1605Heart of America Eye Care Congress ................ 934Heidelberg Engineering ..................................... 717Heine USA ......................................................... 201

Horizon Therapeutics ........................................ 533Hoya Vision Care & Optikam Tech .................. 1519Icare Tonometers ............................................... 517IDOC .................................................................. 408Illuminix Industries ............................................ 206iMatrix ............................................................. 1312Indigo Iris Designs .......................................... 1425Innova Systems ............................................... 1719Invision Magazine ............................................. 417Irisvision .......................................................... 1421Johnson & Johnson Vision............................. 1201Kala Pharmaceuticals ...................................... 1227Keeler Instruments........................................... 1213Kentucky College of Optometry ......................... 623Konan Medical USA ........................................ 1211Wolters Kluwer Health ....................................... 601Lombart Instrument ........................................... 519Lumenis ............................................................. 618

Luneau Technology USA ................................. 1501M&S Technologies .......................................... 1412MacuHealth ..................................................... 1500MacuLogix ........................................................ 203Marco ................................................................ 516Maxivision ......................................................... 301MedPhoto Manager......................................... 1700MedTech International Group .......................... 1028Menicon America .............................................. 609Midwestern U. Arizona College of Optometry &

Chicago College of Optometry ..................... 616Myco Industries/AB Max ................................... 511National Board of Examiners in Optometry ....... 305Nat. Org. for Albinism and Hypopigmentation .. 720National Vision .................................................. 707Nidek ............................................................... 1338Norwood Device & Diagnostics ........................ 529Nova Southeastern University ........................... 303

AAO TIMES8

The Academy 2019 Orlando and 3rd World Congress of Optometry exhibit hall is the perfect place to experience cutting-edge products and services. Badges are required for admission.

ENTRANCE

Exhibit Hall Hours: Wednesday 5–7:30pm • Thursday 10am–6:30pm • Friday 10am–3pm

Special Events: Opening Night Welcome Reception ~ Wednesday 5–7:30pm Student Focus Hours ~ Thursday 10–11:30am Lunch in the Exhibit Hall ~ Thursday and Friday 11:30am–1:30pm Attendee Reception ~ Thursday 5–6:30pm


REVIEW OF OPTOMETRY • SECO SHOW DAILY • MARCH 2, 2018REVIEW OF OPTOMETRY • AAO TIMES • OCTOBER 24, 2019

Novabay Pharmaceuticals ............................... 1405NovaSight .......................................................... 928NuSight Medical................................................ 832Ocular Innovations ............................................ 521Oculus ............................................................... 822Ocusoft ............................................................ 1600Ocutech ........................................................... 1505OptiLanes ........................................................ 1032Opto Multimedia................................................ 806Optometric Architects ...................................... 1410Optometry Times ............................................... 509OptoPrep ........................................................... 704Optos ................................................................. 501Optovue ............................................................. 933Paragon Vision Sciences .................................. 718Salus University PA College of Optometry ...... 1313PentaVision ..................................................... 1326PlenOptika ......................................................... 309

Precision Vision .............................................. 1419Primary Care Optometry News & Healio ........... 304Prudential Advisors ........................................... 732Public Health & Environmental Vision Section and

Vision in Aging SIG .................................... 1733Quantel Medical ................................................ 700Quidel ............................................................... 311Regeneron Pharmaceuticals ............................. 423Reichert Technologies ....................................... 816Review of Optometry ....................................... 1327RightEye .......................................................... 1430RxLoupes........................................................... 107ScienceBased Health ......................................... 525Scope Health ................................................... 1721SEE International ............................................... 628Novartis Pharmaceuticals ................................ 1219Sight Sciences ................................................... 317Solutionreach .................................................... 402

Spark Therapeutics .......................................... 1504Specsy ............................................................... 606Sun Ophthalmics ............................................. 1409Surgenex ........................................................... 320SynergEyes ........................................................ 400Tangible Science ............................................... 633Telscreen ......................................................... 1331The Dry Eye Doctor ........................................... 624The Pixel Fund – Puppies ............................... 1609Think About Your Eyes .................................... 1431Topcon Medical Systems .................................. 729TruForm Optics ................................................. 419Univ. MO St. Louis College of Optometry ....... 1428Valley Contax..................................................... 217Virtual Field ....................................................... 630Vision Associates .............................................. 221Vision Group Holdings...................................... 835Vision Impact Institute ..................................... 1330

Vision Service Plan ......................................... 1520Visionary ........................................................... 608Visionary Optics ................................................ 404Visioneering Technologies ................................ 600Vital Tears ........................................................ 1426Vivid Vision ....................................................... 327Vmax Vision ...................................................... 605Volk Optical ....................................................... 209VOSH International ............................................ 622Vrmagic ............................................................. 828Weave ................................................................ 610Weave .............................................................. 1518Western University College of Optometry ......... 523World Council of Optometry ........................... 1530Younger Optics .................................................. 602Zeiss .................................................................. 701Zilia .................................................................... 224Zoomax ............................................................ 1603

9AAO TIMES

ENTRANCE


AAO TIMES10

2019 Ocular Photography Contest Winners

The 2019 Comprehensive Eye Care Section Annual Ocular Photography Contest received 158 image submissions from 88 different optometrists. The submissions were divided into anterior and posterior segment categories, which received 93 and 65 submissions, respectively. Grand prizes were awarded for the anterior and posterior segments, followed by four honorable mentions from the combined submissions.

Submissions were graded in seven categories, each assigned a numerical value between 1 and 10: focus, exposure, field of view, difficulty of capturing im-age, absence of distracting elements, lighting and visual impact (wow! factor). The total scores from 16 optometrist judges were averaged to determine the winners.

Special thanks to our judges: Erin Brooks, Krista Davis, Christine Giblin, Amy Huddleston, Amanda Jimenez, Danica Marrelli, Albert Nemiroff, Devina Patel, Heema Patel, Glenn Saxon, Mollie Saxon, Melissa Turner, Brooke Vegas, Karen Wadhams, Bryan Wolynski and Nadia Zalatimo.

Vinodh Kumar Uttaravilli, B. Optom.LV Prasad Eye Institute, Visakhapatnam, Andhra Pradesh, India

Benign Fleck RetinaImage system used: Zeiss FF450IR

A 40-year-old male reported for a routine eye exam with visual acuities of 20/20 in the right eye and no light perception in the left. Upon ocular examination of the right eye, the anterior segment was unremarkable and the posterior segment showed multiple yellowish flecks in the retina, only sparing the fovea. The left eye was significant for phthisis bulbi status-post trauma. The patient did not have any history of night blindness.

Krushna Gopal Panda, M. Optom LV Prasad Eye Institute, Mithu Tulsi Chanrai Campus, Bhubaneswar, Odisha, India

Pigmented KeratitisImaging system used: Zeiss FF450 Fundus Camera

A 65-year-old female complained of blurred vision in the right eye for one year. On examination, her best-corrected visual acuity in that eye was light perception with projection. Slit lamp biomicroscopy of the right eye showed multiple pigmented, raised lesions on the cornea.

Grand Prize: Anterior Segment

Grand Prize: Posterior Segment



Honorable Mention #4:

Steven G. Ferrucci, OD, FAAO, Sepulveda VA, North Hills, CA, USA Special Acknowledgement: Brenda Yeh

Bilateral Choroidal MetastasisImage system used: Eidon AF True Color Confocal Scanner

A 63-year-old male with lung cancer presented complaining of decreased vision in the right eye. Examination revealed bilateral choroidal metastases. Patient declined all treatment and died four

months after this photo was taken.


Corinne N. Casey, OD, FAAO

Katzen Eye Group, Baltimore, MD, USA

Valsalva MaculopathyImage system used:Zeiss Cirrus Photo 600

A 22-year-old African-American female presented with concerns of sudden-onset unilateral vision loss after an episode of vomiting

attributed to morning sickness. She was 12 weeks pregnant with no other known medical conditions. Fundus examination revealed a

resolving subhyaloid macular hemorrhage in the left eye.

11AAO TIMES



Charlie V. Ngo, OD, FAAO

UC Berkeley School of Optometry, Berkeley, CA, USA

ToxoplasmosisImaging Topcon Fundus Camera

A young Latin American female presenting with long-standing blurry vision.


Charlie V. Ngo, OD, FAAO

UC Berkeley School of Optometry, Berkeley, CA, USA

Choroidal Folds Secondary to Orbital TumorImage system used: Topcon Fundus Camera

A young Latin American male presenting with new-onset proptosis.

Honorable Mentions


AAO TIMES12


Did you know that the Academy is more than just a meeting?We invite you to become a Fellow of the American Academy of Optometry (FAAO) and to join a group of professionals dedicated to the highest standards in patient care. Visit the Academy’s membership booth in the Exhibit Hall (#1527) to meet current Fellows of the Academy, ask questions, and learn more about the Candidacy for Fellowship process. Also, if you submit your Candidacy for Fellowship application during the meeting, we will waive the application fee (that’s a savings of $60)!We also invite you to join us for the Fellowship Information Session being held TODAY from 3–4pm in W240 AB.

Attention OD Students, Residents and Post-Doctoral Students! Stop by the booth to pick up Academy information or apply for student membership.

Did you graduate from optometry school in 2019? If so, submit your Candidacy for Fellowship application by the end of the year and we will waive your 2020 Academy dues. Visit the Academy booth for more information.

CONTINUING EDUCATION WITH EXAMINATION (CEE) CREDITS AT ACADEMY 2019 ORLANDO AND 3RD WORLD CONGRESS OF OPTOMETRYThe courses listed below will be presented with an option to take an exam, administered by the University of Houston College of Optometry. All CEE exams are offered online. All are welcome to attend the courses without taking the exam. Instructions to request the exams are available at the Education Desk.


Time Course # Course Title Lecturer(s) Room

9 –11am AS-06 Therapeutic Treatment Tales: Fact or Fiction Tammy Than, Blair Lonsberry Tangerine WF 3/4

10am–12pm PS-08 Diagnosis and Treatment of Peripheral Retinal Disease Mohammad Rafieetary Tangerine WF2

10am–12pm, SD-05 Trauma Drama: Cases of Mechanical Ocular Inquiry Jeffrey Gerson, A. Paul Chous W315 AB

1:30–3:30pm PS-09 AMD - How to Improve Outcomes and Help Prevent Blindness Damon Dierker, Brad Sutton Tangerine WF1

1:30–3:30pm GO-07 The Oculoplastic Optometric Physician Selina McGee W331

2:30–4:30pm GO-09 Pediatrics for the Primary Care Optometrist Marianne Boltz W230 CD

3:30–5:30pm LV-05 Clinical Optics for Low Vision Rehabilitation David Lewerenz W232

3:30–5:30pm SD-09 Understanding Clinical Significance of Common Retinal Lesions Thomas Freddo W331

3:30–5:30pm OP-03 Oral Pharmaceuticals in Anterior Segment Disease Nathan Lighthizer, Blair Lonsberry Valencia AB

Friday, October 25

8–10am GO-16 The Use of VEPs, ERGs, and EOGs and Updates in Clinical Practice Kimberley Poirier-Schmidt, Sherry Bass W224 DH

8–10am OP-04 Complications of Pharmaceuticals Every Optometrist Should Know Greg Caldwell, Tracy Offerdahl Tangerine WF2

9–11am SD-13 Uveitis Associated with Systemic Disease Megan Hunter, Michelle Marciniak Tangerine WF1

10am–12pm AS-10 Microbial Keratitis: Bacterial and Non-Bacterial Update Joseph Shovlin, Michael DePaolis, Paul Karpecki Tangerine WF2

2–4pm RS-02 Unlocking the Potential of Refractive Surgery in Your Practice Kyle Sandberg, Roberto Saenz, Michael Shumski W230 CD

2–4pm NO-11 Pathways to a Proper Diagnosis Kelly Malloy, Lorraine Lombardi Tangerine WF 3/4

4–6pm OP-05 Pain Management for the OD Jane Grogg Tangerine WF 3/4

Saturday, October 26

8–10am SP-02 Lids and Lashes on the Cutting Edge Spencer Johnson W231

8–10am NO-12 Neuro-ophthalmic Disorders Update Joseph Sowka, Greg Caldwell, Jessica Steen Tangerine WF2

1–3pm SD-15 Hypertension: When Things Go Awry Not Only in the Eye Kimberley Poirier-Schmidt, Carlo Pelino Tangerine WF 3/4


13AAO TIMES


Thomas E. Levy, MD, JD, will present, “Vitamin C and Magnesium: The Master

Supplements,” tonight at 7pm over dinner at the fall symposium of the Ocular Wellness and Nutrition Society (OWNS).

Dr. Levy will open the talk by pinpointing what he will argue is the cause of all disease: increased intracellular oxidative stress (IOS). This occurs when free radicals prevent the body from reducing them or controlling their produc-tion, a process that involves toxins, pathogens and nutrients. Capable of restoring the body’s antioxidant capacity is vitamin C, which is an effective anti-toxin. Vitamin C is one of four main determinants of IOS. Rounding out this list are calcium, magnesium and glutathione.

Dr. Levy will fi rst focus on calcium, a higher intracellular concentration of which is the primary contributor to increased IOS and risk of mortality, disease and heart attack. Manipu-lating intracellular calcium levels positively impacts IOS and, therefore, all disease process-

es. Calcium level is indirectly proportional to magnesium level, while vitamin C moves on the same wavelength as magnesium. When it comes to glutathione, the body will only maintain normal glutathione levels when the other three modulators and IOS normalize, encouraging intracellular glutathione synthesis.

Dr. Levy will also discuss the part hor-mones—specifi cally insulin, hydrocortisone, estrogen, testosterone and thyroid—play in nor-malizing IOS and how they optimize cell func-tion, making them comparable to vitamin C and magnesium. These six agents should always be involved in medical management, as curing a disease means stabilizing IOS by manipulating each of their levels.

While administering high doses of vitamin C is usually effective, Dr. Levy will touch on other ways to optimize the antioxidant’s intracellular levels. These include promoting and maintain-ing optimal critical hormone levels, body-wide magnesium levels, digestion and additional

supplementation as well as eliminating or containing focal infections. Further increasing vitamin C’s utility, he will explain, is a new nutrient polyphenol supplement that helps the liver synthesize it.

Dr. Levy will conclude the night by empha-sizing that maintaining a high vitamin C intake reduces the incidence of ocular problems, such as cataract, glaucoma and AMD, and enhances corneal healing and overall health.

This important topic, and ocular nutrition as a whole, should be on every provider’s radar. OWNS is committed to raising the awareness of practicing health providers to counteract an outdated approach to eye care and medicine that focuses on symptom-based—not wellness-based—care. To join the new era of wellness-based care and build a network of like-minded colleagues, practitioners can become members of OWNS, and set out on a path toward an OWNS Fellowship and even a nutrition special-ist certifi cation. •

Become a Master of SupplementsOWNS members will gather to discuss vitamin C and several other antioxidant heavy-hitters.

Patients with adenoviral conjunctivi-tis who received a one-time, in-offi ce

application of 5% povidone-iodine (PVP-I) showed improvement in signs and symp-toms, lower viral titers and lower IL-8 levels after four days, compared with participants who received artifi cial tears in a recent study. Tammy Than, MS, OD, FAAO, a staff optometrist at the Carl Vinson VA Medical Center in Dublin, Georgia, presented the pilot fi ndings of the Reducing Adenoviral Patient-Infected Days (RAPID) study, a double-masked randomized pilot trial of 5% Betadine (povidone-iodine, Avrio Health) for treatment of adenoviral conjunctivitis.

At day four, adenoviral titers had decreased to 2.5% in the Betadine group, relative to peak titer levels (100%) measured at one of the fi rst two visits, while titers decreased to 14.4% in the artifi cial tears group.

RESEARCH SPOTLIGHTEfficacy of Single Administration of 5% Povidone-Iodine in the Treatment of Adenoviral Conjunctivitis Tammy P. Than, Andrew T. Hartwick, et al.

Detecting Retinal Changes using Machine Learning in Diabetics Without Retinopathy Christopher A. Clark, Ann E. Elsner

We can use machine learning to detect changes in the retinal structure before

the development of retinopathy, according to Christopher Clark, OD, PhD. Researchers wanted to see if they could correlate chang-es in hA1C levels, a standard for assessing overall blood glucose control with changes in retinal structure that are not detectable through current means such as tra-ditional OCT and fundus photography. They trained and tested the machine learning models with 8,760 images of diagnosed diabetics with a wide range of HA1c but without retinopathy. The best model correctly predicted 1,099 above six HA1C, 1,049 predicted below. It categorized 771 images in the wrong level. Dr. Clark hopes that the using the model could potentially reduce unnecessary visits for diabetics with otherwise healthy retinas and detect systemic diabetes in patients currently not diagnosed with diabetes.

TONIGHT 7–10pm CUBA LIBRE

The above summary was presented at the Academy press conference yesterday. Dr. Than will give a full presentation of the study today in this session:

Hot Topics in Anterior Segment Thursday 8:00-8:15am, Tangerine WF2

The above summary was presented at the Academy press conference yesterday. Dr. Clark will give a full presentation of the study today in this session:

Hot Topics in Artificial Intelligence Thursday 8:30-8:45am, Tangerine WF3/4


AAO TIMES14

Epidemiology Hits Home: The Human Side of Stats

Yesterday’s Ezell Fellow speak-ers proved just how crucial research is to optometry in

“Ezell Fellows Present: Public Health/Epidemiology Potpourri.” It affects everything from what contact lens solutions you recommend to which patients are prone to keratitis, and even which US regions are hit hardest by vision impairment. Moderated by Daniel Roberts, OD, PhD, FAAO, the session was packed with pro-found research implications.

Keratitis in Your GenesNicole Carnt, BOptom (Hons), PhD, FAAO, kicked off the session with a detailed analysis of contact lens-associated keratitis—and it’s not just a condition for those who are noncompliant, she said.

“Some people do everything wrong and nothing happens, while others do just one thing wrong and they experi-ence a catastrophic event,” Dr. Carnt noted. “I wanted to know why.”

Dr. Carnt explored the many modifi able and nonmodifi able risk factors for Acanthamoeba keratitis (AK), noting that some patients are more prone to the condition given their ocular anatomy, tear fi lm com-position and innate ocular surface de-fense. Her research also shows some are actually predisposed to keratitis because of their genes.

While clinicians may not be able to change those factors, they can ad-

dress many other modifi able factors to help reduce the risk of keratitis. If clinicians can stop patients from sleeping in their contact lenses, they could cut the incidence of keratitis by a whopping 43%, she said.

Numbers Tell a StoryCharlotte Joslin, OD, PhD, FAAO, then provided attendees a glimpse of her epidemiology work on every-thing from AK to big data analysis of IOP’s association with systemic disease, AMD and neuro-ophthalmic conditions. Her research on the 2006 increase in AK in Chicago helped uncover an association with a single soft contact lens solution, and she has also noticed a shifting AK case distribution over two years, incon-sistent with known risk factors. This suggests as-yet unidentifi ed risk fac-tors are impacting disease prevalence, she told attendees.

“Big data studies are great for rare diseases and providing information on outcomes,” she told her audience. To prove it, she shared her fi ndings on IOP’s link with conditions other than glaucoma, including obesity, diabetes and systolic hypertension. These results shed light on several modifi able factors associated with IOP control, she said, and are partic-ularly important for clinicians caring for patients with obesity and diabe-tes—both of which are on the rise in the United States. The data show that those who are prone to increased pressure are also more likely to have variable pressure, which could con-found in-offi ce readings, she noted.

Another of her studies clarifi ed the link between AMD and mortality. “Our big data analysis shows that AMD is associated with all-cause and CVD-specifi c mortality, and sex modifi es that association,” she said.

Datasets Set the StageThe CDC is a wealth of information, and uses several surveillance tools to track health data in the United States, according to the session’s fi nal expert, Dean VanNasdale, OD, PhD, FAAO. However, “we really aren’t good at collecting data on vision impair-ment,” he admitted. “Added to that, what we do collect isn’t uniform.”

Dr. VanNasdale showed attendees exactly what he meant by this. Two national surveys, the Behavioral Risk Factor Surveillance System (BRFSS) and the American Community Survey (ACS), ask patients the same question about blindness and vision impair-ment—and yet they provide differing statistics. The BRFSS found an over-all prevalence of vision impairment of 4.6% in 2015, while the ACS set it at 2.3% for the same year. “They really aren’t comparable,” he explained.

Nonetheless, these tools provide crucial information, he told attend-ees. For example, he and his team now know patients with vision impairment are nearly twice as likely to also have arthritis than those with normal vision. He found southern

states are hit harder by vision loss than northern states. This led to state-specifi c analyses, which “will help us better understand who isn’t getting the care they need and help us advocate for better resources in those areas” he said. •


Researchers have developed an automated glaucoma detec-

tion model from OCT retinal images at clinician accuracy levels using a deep learning technique with transfer-learning based convolu-tional neural network. The study used the neural network to classify eyes as normal or glaucoma. Two modifi ed transfer learning architec-tures, Alexnet and Inception-v3, were trained and evaluated. The fi ndings revealed that the accuracy for validation data was 93% and 96%, sensitivity was 87% and 92% and specifi city was both 100% for Alexnet and Inception-v3, respec-tively. In future tests, the research-ers will increase the data size to get the optimal result.

RESEARCH SPOTLIGHT

A Feature Agnostic-based Glaucoma Diagnosis From OCT Images With Deep Learning Technique

Nahida Akter, Adam Li, Rocky Shi, Jack Phu, Stuart Perry, John Fletcher, Maitreyee Roy

Former Ezell Fellowship recipients teamed up to share new insights into three research areas making waves.

Exhibit Hall Opening Feeds Attendees’ Curiosity—and AppetitesOptometrists and other eye care professionals crowded the conference hall eagerly awaiting yesterday’s Exhibit hall grand opening. At 5pm sharp, the doors swung open and gave attendees their fi rst look at everything this year’s expansive hall has to offer—includ-ing food stations providing refreshments as part of the welcome reception. Drinks and treats in hand, conference goers wasted no time spreading

out to browse through nearly 200 industry booths to gather information and fi ll their totes.

EXHIBIT HALL OPENING CEREMONY

Dr. VanNasdale helped to create state-specifi c infographics that include multiple data sources—a signifi cantly better way to understand the impact of vision impairment in the United States.

The above summary was presented at the Academy press conference yesterday. Dr. Akter will give a full presentation of the study this morning in the following session:

Hot Topics in Artificial Intelligence 8–9am, Tangerine WF3/4


Visit our website for the latest information: www.reviewsce.com/eventse-mail: [email protected] or call: 866-658-1772

2020 MEETINGSJoin us for our

Earn up to18-28 CE

Credits*

FEBRUARY 14-17, 2020 - ASPEN, COAnnual Winter Ophthalmic ConferenceWestin Snowmass Conference CenterProgram Co-chairs: Murray Fingeret, OD, FAAO and Leo P. Semes, OD, FACMO, FAAO

REGISTER ONLINE: www.skivision.com

JUNE 5-7, 2020 - ORLANDO, FLDisney Yacht & Beach ClubProgram Chair: Paul M. Karpecki, OD, FAAO

REGISTER ONLINE: www.reviewsce.com/orlando2020

J

MAY 29-31, 2020 - SAN DIEGO, CAManchester Grand HyattProgram Chair: Paul M. Karpecki, OD, FAAO

REGISTER ONLINE: www.reviewsce.com/sandiego2020

APRIL 16-19, 2020 - AUSTIN, TXOmni Barton CreekJoint Meeting with OCCRS**

Program Chair: Paul M. Karpecki, OD, FAAO

REGISTER ONLINE: www.reviewsce.com/austin2020

A

J

NOVEMBER 6-8, 2020 - PHILADELPHIA, PAPhiladelphia Marriott DowntownProgram Chair: Paul M. Karpecki, OD, FAAO

REGISTER ONLINE: www.reviewsce.com/philadelphia2020

Review Education Group partners with Salus University for those ODs who are licensed in states that require university credit.See www.reviewsce.com/events for any meeting schedule changes or updates.

NEW TECHNOLOGIES & TREATMENTS IN

Eye CareNENEW W TNENEW T &&& T && T

2020 00

**17th Annual Education Symposium

Joint Meeting with NT&T in Eye Care*Approval pending

Administered by:

*Annual supply purchases among leading brands purchased between 1/1/18 and 12/31/18. †Purchased an annual supply of contact lens brand in 2017 and then repurchased an annual supply of the same brand in 2018.

REFERENCE: 1. Data on file. Bausch & Lomb Incorporated. 3rd Party Industry Report. 2017-2018.

Biotrue and inspired by the biology of your eyes are trademarks of Bausch & Lomb Incorporated or its affiliates.All other products/brand names and/or logos are trademarks of the respective owners.©2019 Bausch & Lomb Incorporated or its affiliates. BOD.0310.USA.19

LOOK NO FURTHERBiotrue® ONEday had the highest

annual supply rate and repurchase rate among leading brands.1

a

From a sampling of over 50,000 patients, Biotrue® ONEday was #1 in:

ANNUAL SUPPLY RATE* REPURCHASE RATE†

40

30

20

10

0

32%

28%

27%

24%22%

21%

8%

54%52%

60

50

40

30

20

10

0

50%49%

41%39%

26%

Biotrue® ONEday clariti 1 day

DAILIES AquaComfort

Plus

ACUVUEOASYS 1-DAY

1-DAY ACUVUE MOIST

DAILIES TOTAL1

ACUVUE OASYS 2-WEEK

Biotrue® ONEday clariti 1 day

DAILIES AquaComfort

Plus

ACUVUEOASYS 1-DAY

1-DAY ACUVUE MOIST

DAILIES TOTAL1

ACUVUE OASYS 2-WEEK

For the leading annual supply sales and patient repurchases, look no further than Biotrue® ONEday.

AAO2019_Bausch+Lomb.indd 1 10/22/19 12:20 PM

plenary: address global eye care needs...a patient is young—think elemen-tary school age—and...

Documents